Zydus Lifesciences: Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a…
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure titled "Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka". The company is valued at about ₹1.12 lakh crore.
What happened
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure with the exchanges on 15 October 2026 at 11:31 AM titled "Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka".
Company snapshot
Zydus Lifesciences is a large-cap company in the Healthcare sector, with a market value of about ₹1.12 lakh crore.
The stock last traded at ₹1,124.7, against a 52-week range of ₹835.5–₹1,232.1 (8.7% below the high).
Before this filing the shares had moved +0.5% over the month and −2.5% over three months. Average daily turnover over the last 20 sessions was about ₹192 crore.
Promoters held 75.01% at the end of Q1 FY27. Foreign institutions owned 6.88% and domestic institutions 11.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,574 | 1,466.8 | 14.58 |
| Q2 FY26 | 6,123 | 1,258.6 | 12.51 |
| Q3 FY26 | 6,865 | 1,042.1 | 10.36 |
| Q4 FY26 | 7,587 | 1,272.5 | 12.65 |
| Q1 FY27 | 8,017 | 939.8 | 9.35 |
What history shows
BCEIE has no earlier similar filing from this company on record since May 2026.
Market-wide, 108 similar filings with an impact score of 50 or more saw an average next-day move of +0.7%, with 46% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
- Zydus Lifesciences Moraiya Plant USFDA Inspection Concludes With 5 Observations
- ZYDUSLIFE Share Price Today - Zydus Life Science on NSE/BSE
- Zydus Lifesciences, MSN Laboratories Launch First Generic of Adempas in US
- Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations
- Mankind Pharma, Zydus Lifesciences among top losers, fall up to 3% after Supreme Court asks Centre to...
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.